Arcutis Biotherapeutics, Inc. (ARQT) vs Tarsus Pharmaceuticals, Inc. (TARS)
Arcutis Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. are of similar size ($3.6B and $3.4B). Tarsus Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 122×. Tarsus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 105.2% against 76.1%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −7.67%) and the higher return on invested capital (23.6% vs 0.00%). Across the 18 metrics below, Tarsus Pharmaceuticals, Inc. leads on 11 and Arcutis Biotherapeutics, Inc. on 7.
Valuation
Profitability
| Metric | ARQT | TARS | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 93.28% | 65.16% |
| Operating margin | 7.38% | (8.00%) | 0.00% |
| Net margin | 6.15% | (7.67%) | 0.00% |
| Free cash flow margin | 8.42% | 9.24% | 0.00% |
| Return on equity | 15.86% | (13.68%) | (57.72%) |
| Return on assets | 6.78% | (8.40%) | (49.22%) |
| Return on invested capital | 23.62% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack